Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Neurocrine Biosciences Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.78 (market cap $5.86B), while Neurocrine Biosciences Inc trades at $142.61 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.5× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 60 Days and Neurocrine Biosciences Inc for 23 Days on average.
| JNK | NBIX | |
|---|---|---|
Market Cap | $5.86B | $14.36B |
Volume | 7,780,002 | 1,237,180 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $185.50 |
52-Week Low | $92.30 | $123.10 |
Typical Hold Time | 60 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.695 with a slight 0.07% decline, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions of $0.53 per share through mid-2026. Recent market focus centers on high-yield bond dynamics amid rising Treasury yields and institutional positioning changes.
The high-yield bond ETF faces headwinds from rising interest rates but benefits from institutional accumulation. Key risks include bond market volatility and economic sensitivity, while the consistent dividend stream provides income appeal for yield-seeking investors in the current rate environment.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
